| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
IC50: 54.3 μg/mL (Glucosyltransferase (GTase)[2]
The primary targets of isoastilbin include glucosyltransferase (GTase) and tyrosinase. Isoastilbin inhibits GTase with an IC₅₀ of 54.3 μg/mL and also inhibits tyrosinase activity. The compound has neuro-protective, antioxidant, antimicrobial, and anti-apoptotic properties. Isoastilbin may be used in Alzheimer's disease studies. |
|---|---|
| ln Vitro |
In vitro studies have demonstrated the biological activities of isoastilbin. The compound inhibits glucosyltransferase with an IC₅₀ of 54.3 μg/mL. Isoastilbin also inhibits tyrosinase activity. The compound has antimicrobial and antioxidant activities. These activities support its potential for further investigation.
|
| ln Vivo |
In vivo activity of isoastilbin has been studied in the context of its neuroprotective and antioxidant effects. The compound may be used in Alzheimer's disease studies. Specific in vivo data have been reported in the literature. Further studies are needed to fully characterize its in vivo efficacy.
|
| Enzyme Assay |
For enzyme inhibition assays, glucosyltransferase or tyrosinase is incubated with a substrate in the presence of isoastilbin. Enzyme activity is measured spectrophotometrically. IC₅₀ values are calculated from dose-response curves. For antioxidant assays, DPPH or other radical scavenging methods are used.
|
| Cell Assay |
For in vitro cell-based studies, various cell lines may be used to evaluate the compound's neuroprotective and antimicrobial activities. Cells are cultured in appropriate media and treated with serial dilutions of isoastilbin. Cell viability and markers of oxidative stress are measured. Standard protocols for these assays are described in the literature.
|
| Animal Protocol |
In vivo animal studies for isoastilbin have been conducted in models of Alzheimer's disease. The compound's neuroprotective effects have been evaluated. Standard protocols for in vivo efficacy studies are described in the literature.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of isoastilbin have not been extensively characterized. As a glycoside with a molecular weight of 450.40 g/mol, it may have limited oral bioavailability. The compound is typically stored at 2-8°C. Specific PK parameters such as half-life and bioavailability have not been reported.
|
| Toxicity/Toxicokinetics |
Toxicological data for isoastilbin are limited. As a natural product, it may have a favorable safety profile. However, systematic toxicological studies have not been extensively published. The compound is for research use only and is not intended for human therapeutic use.
|
| References |
|
| Additional Infomation |
Astebenzin is a flavanone glycoside formed by the substitution of (+)-taxanthin at the 3-position by an α-L-rhamnosyl group via a glycosidic bond. It possesses free radical scavenging, anti-inflammatory, and plant metabolite activity. It is an α-L-rhamnosyl glycoside belonging to the 3'-hydroxyflavanone, tetrahydroxyflavanone, flavanone glycoside, monosaccharide derivative, and 4'-hydroxyflavanone classes. Functionally, it is related to (+)-taxanthin. It is the enantiomer of neoastebenzin. Astebenzin has been reported in Neolitsea aurata, Hymenaea martiana, and other organisms with relevant data. Astebenzin is a metabolite found or produced in Saccharomyces cerevisiae.
Isoastilbin is a research compound used in studies of dihydroflavonol glycosides. It has anti-acne and tyrosinase inhibition properties. Isoastilbin, neoastilbin, astilbin, and taxifolin have antimicrobial activities. The compound may be used in Alzheimer's disease studies. No clinical trials or therapeutic applications have been reported. |
| Molecular Formula |
C21H22O11
|
|---|---|
| Molecular Weight |
450.39
|
| Exact Mass |
450.116
|
| CAS # |
54081-48-0
|
| PubChem CID |
119258
|
| Appearance |
White to off-white solid powder
|
| Density |
1.7±0.1 g/cm3
|
| Boiling Point |
801.1±65.0 °C at 760 mmHg
|
| Melting Point |
179 - 180 °C
|
| Flash Point |
282.9±27.8 °C
|
| Vapour Pressure |
0.0±3.0 mmHg at 25°C
|
| Index of Refraction |
1.748
|
| Source |
Originated from plants: other families
|
| LogP |
2.97
|
| Hydrogen Bond Donor Count |
7
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
32
|
| Complexity |
676
|
| Defined Atom Stereocenter Count |
7
|
| SMILES |
C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@@H]2[C@H](OC3=CC(=CC(=C3C2=O)O)O)C4=CC(=C(C=C4)O)O)O)O)O
|
| InChi Key |
ZROGCCBNZBKLEL-MPRHSVQHSA-N
|
| InChi Code |
InChI=1S/C21H22O11/c1-7-15(26)17(28)18(29)21(30-7)32-20-16(27)14-12(25)5-9(22)6-13(14)31-19(20)8-2-3-10(23)11(24)4-8/h2-7,15,17-26,28-29H,1H3/t7-,15-,17+,18+,19+,20-,21-/m0/s1
|
| Chemical Name |
(2R,3R)-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy-2,3-dihydrochromen-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~16.7 mg/mL (~37.0 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.67 mg/mL (3.71 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (16.7 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.67 mg/mL (3.71 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (16.7 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 1.67 mg/mL (3.71 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (16.7 mg/mL) to 900 μL of corn oil and mix well. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2203 mL | 11.1015 mL | 22.2030 mL | |
| 5 mM | 0.4441 mL | 2.2203 mL | 4.4406 mL | |
| 10 mM | 0.2220 mL | 1.1101 mL | 2.2203 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
